Vakston is a developer of Fc-fusion-based vaccines and boosters for infectious disease applications worldwide. It delivers durable, best-in-class safety, and broad-spectrum immunity with room-temperature stability, enabling affordability and global access.

Pet‑focused biotech powering species‑specific protein therapeutics through its Ambifect® Fc‑fusion platform. Akston combines vertically integrated discovery-to‑manufacturing with best-in-class long‑acting, cost‑effective treatments for obesity, cancer, pain, and more.

Reimagining hospital beds as diagnostic and therapeutic devices. LeviSense’s sensor-cell tech monitors and manages airflow, pressure, and skin health to prevent and heal bedsores.

Cracking diseases hiding outside the human exome.
 NonExomics finds novel proteins in the so-called “junk” genome and turns them into drug targets for rare and inherited diseases.

Aquired

Upgrading pathology labs with faster, simpler staining kits.
 Cell IDx builds high-performance tools for tissue diagnostics—faster turnaround, easier workflow, better results. Danaher acquired Cell IDx in 2022.

Diagnosing brain disease from a single blood draw.
 NeuroDex isolates neurological exosomes from blood to detect and track disease—no spinal taps, no guesswork.

More signal, less noise in proteomics.
 AdepTrix’s BAMS tech boosts protein mass spec sensitivity with targeted reagents, unlocking next-gen biomarker discovery.

Painting tumors for precision attack.
 TriBiotica’s haplomers bind to tumor cell surfaces, creating new drug targets for immunotherapy.

A new shot at brain diseases.
Twilight is developing a precision immunotherapy approach to Alzheimer’s, chronic pain and a number of neurodegenerative diseases.  Twilight is the first graduate of Formation VE's in-house research studio, FVE Foundry.  

Making DNA tools faster, cheaper, greener.
 Oligo Foundry builds scalable platforms for oligo synthesis and conjugation—fueling innovation in diagnostics and therapeutics.